Kevin Brewer
Analyst · Tom Diffely with D.A. Davidson. You may now ask your question
Yeah, so I mean, eval volumes have a negative effect. Some of the evals have higher costs and others don't so that certainly moves in a number of the eval. And I think what's going on in Q1 is that the evals going now, we've also got a higher mix of high current tools gone out which overall is good for the company, because that's a large market and that's one of the areas we want to continue to grow in this high current. But maybe that could help you a little bit more. If I look at the full year right now Tom, I'm seeing full year gross margin in 2021 similar to what they were in 2020. And that includes a number of evals for analysis, as Mary says, we've got, so one closed not only going out with six, and I think as you recall, typically, we would have two or three. So, we've been saying for the last couple of quarters is a high number of evals and more going. So, those are sitting in on the margins. And the other thing, we're going to see a lot of growth this year coming from systems versus CS&I, right. So, as the systems grow next year in CS&I, that can pressure things a little bit. But the good news is, what all are there in the growth in systems, all these evals, I put this point, we expect gross margins for year to finish similar to last year. And our target model is 42 to 43, on 550. So, we're just off of that a tiny bit. And if you look at, try to do the math and figure when I get there, and I think about cost initiatives, maybe we get there a little bit sooner than we thought, some of these initiatives still have to kick in. So, from a gross margin point of view, I feel really good where we are right now. And expect this year to continue to drive cost out and get the value in kind of a more Purion product extensions, and those are all things we need to get to our model. And then the 650 model, the margins are up to 44 to 45. And that's a couple years later. So, we're - again, we're in good shape Tom.